Table 3 Two-step MR results of VLDL as a mediator variable for AD and cancer
VLDL | nsnp | β | se | pval | Q | Q_df | Q_pval | |
|---|---|---|---|---|---|---|---|---|
AD as the exposure and VLDL as the outcome | L.VLDL.C | 10 | 0.1109 | 0.0298 | 0.0002 | 18.0300 | 9 | 0.0348 |
L.VLDL.CE | 10 | 0.0969 | 0.0298 | 0.0012 | 16.9641 | 9 | 0.0493 | |
L.VLDL.PL | 10 | 0.1416 | 0.0293 | 0.0000 | 17.3709 | 9 | 0.0432 | |
S.VLDL.FC | 10 | 0.2240 | 0.0332 | 0.0000 | 22.7703 | 9 | 0.0067 | |
S.VLDL.L | 10 | 0.1986 | 0.0319 | 0.0000 | 19.7753 | 9 | 0.0194 | |
S.VLDL.P | 10 | 0.1840 | 0.0321 | 0.0000 | 19.9873 | 9 | 0.0180 | |
S.VLDL.PL | 10 | 0.1837 | 0.0295 | 0.0000 | 18.0111 | 9 | 0.0350 | |
VLDL as the exposure and endometrial cancer as the outcome | L.VLDL.C | 9 | − 0.1487 | 0.0678 | 0.0282 | 5.9211 | 8 | 0.6561 |
L.VLDL.CE | 11 | − 0.1503 | 0.0696 | 0.0308 | 12.4403 | 10 | 0.2565 | |
L.VLDL.PL | 9 | − 0.1946 | 0.0768 | 0.0112 | 9.8292 | 8 | 0.2773 | |
S.VLDL.FC | 10 | − 0.1523 | 0.0649 | 0.0188 | 9.5730 | 9 | 0.3862 | |
S.VLDL.L | 11 | − 0.1282 | 0.0695 | 0.0650 | 13.3105 | 10 | 0.2070 | |
S.VLDL.P | 12 | − 0.1420 | 0.0759 | 0.0615 | 13.3105 | 10 | 0.2070 | |
S.VLDL.PL | 10 | − 0.1517 | 0.0625 | 0.0153 | 9.5537 | 9 | 0.3879 |
Mediating effect | Direct effect | |||||||
|---|---|---|---|---|---|---|---|---|
AD as the exposure, endometrial cancer as the outcome, and VLDL as the mediator | L.VLDL.C | − 0.0165 | − 0.0826 | |||||
L.VLDL.CE | − 0.0146 | − 0.0845 | ||||||
L.VLDL.PL | − 0.0276 | − 0.0715 | ||||||
S.VLDL.FC | − 0.0341 | − 0.0650 | ||||||
S.VLDL.L | − 0.0255 | − 0.0736 | ||||||
S.VLDL.P | − 0.0261 | − 0.0730 | ||||||
S.VLDL.PL | − 0.0279 | − 0.0712 |